Quarterly Consolidated Balance Sheet

Medrx Co.,Ltd. - Filing #7312833

Concept As at
2024-06-30
As at
2023-12-31
Quarterly consolidated balance sheet
Balance sheet
Assets
Current assets
Cash and deposits
2,166,353,000 JPY
1,720,720,000 JPY
Raw materials and supplies
12,252,000 JPY
10,079,000 JPY
Other
18,325,000 JPY
10,440,000 JPY
Current assets
2,227,898,000 JPY
1,785,015,000 JPY
Non-current assets
Property, plant and equipment
139,956,000 JPY
181,547,000 JPY
Property, plant and equipment
Buildings and structures
Buildings and structures, net
135,438,000 JPY
176,182,000 JPY
Machinery, equipment and vehicles
Machinery, equipment and vehicles, net
2,554,000 JPY
3,066,000 JPY
Investments and other assets
164,909,000 JPY
85,690,000 JPY
Investments and other assets
Investment securities
80,711,000 JPY
JPY
Other
1,549,000 JPY
1,549,000 JPY
Allowance for doubtful accounts
-2,288,000 JPY
-2,288,000 JPY
Non-current assets
304,865,000 JPY
267,237,000 JPY
Assets
2,532,764,000 JPY
2,052,252,000 JPY
Liabilities
Current liabilities
Income taxes payable
7,163,000 JPY
7,661,000 JPY
Other
2,101,000 JPY
1,485,000 JPY
Current liabilities
42,371,000 JPY
99,993,000 JPY
Non-current liabilities
Asset retirement obligations
2,959,000 JPY
22,609,000 JPY
Non-current liabilities
2,959,000 JPY
27,527,000 JPY
Liabilities
45,330,000 JPY
127,520,000 JPY
Net assets
Shareholders' equity
Share capital
376,590,000 JPY
847,504,000 JPY
Capital surplus
2,109,765,000 JPY
1,916,098,000 JPY
Retained earnings
-41,316,000 JPY
-915,728,000 JPY
Treasury shares
0 JPY
0 JPY
Shareholders' equity
2,445,038,000 JPY
1,847,874,000 JPY
Valuation and translation adjustments
Valuation difference on available-for-sale securities
-18,973,000 JPY
JPY
Foreign currency translation adjustment
10,988,000 JPY
10,500,000 JPY
Valuation and translation adjustments
-7,985,000 JPY
10,500,000 JPY
Share acquisition rights
50,381,000 JPY
66,357,000 JPY
Net assets
2,487,434,000 JPY
1,924,731,000 JPY
Liabilities and net assets
2,532,764,000 JPY
2,052,252,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.